<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>DONNATAL EXTENTABSÂ - phenobarbital, hyoscyamine sulfate, atropine sulfate and scopolamine hydrobromideÂ tablet, film coated, extended releaseÂ </strong><br>PBM Pharmaceuticals, Inc<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>Donnatal Extentabs</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-1"></a><p></p>
<h1>Patient Insert</h1>
<p class="First">DONNATAL EXTENTABSÂ®</p>
<p>Rx Only<br></p>
<p> Rev. 06/07 </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>Description:</h1>
<p class="First">Each Donnatal ExtentabsÂ® tablet contains:<br><br>Phenobarbital, USP (3/4 gr.)Â Â  Â 48.6 mg<br>Hyoscyamine Sulfate, USPÂ Â  Â 0.3111 mg<br>Atropine Sulfate, USPÂ Â  Â 0.0582 mg<br>Scopolamine Hydrobromide, USPÂ Â  Â .0.0195 mg<br><br>Each Donnatal ExtentabsÂ® tablet contains the equivalent of three DonnatalÂ® tablets. Extentabs are designed to release the ingrediÂ¬ents gradually to provide effects for up to twelve (12) hours.<br><br>In addition, each tablet contains the following inactive ingredients: Anhydrous Lactose, Calcium Sulfate Granular, Colloidal Silicon Dioxide, Dibasic Calcium Phosphate, Lactose Monohydrate, Magnesium Stearate, and Stearic Acid. Film Coating and Polishing Solution contains: D and C Yellow #10 Aluminum Lake, FD and C Blue #1 Aluminum Lake, Hydroxypropyl Methylcellulose, Polydextrose, Polyethylene Glycol, Titanium Dioxide, and Triacetin.Â  The printing ink contains Titanium Dioxide.</p>
</div>
<div class="Section" data-sectionCode="43679-0">
<a name="section-3"></a><p></p>
<h1>ACTIONS:</h1>
<p class="First">This drug combination provides natural belladonna alkaloids in a specific, fixed ratio combined with phenobarbital to provide peripheral anticholinergic/antispasmodic action and mild sedation.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS</h1>
<p class="First">Based on a review of this drug by the National Academy of Sciences - National Research Council and/or other information, FDA has classified the following indications as â€œpossiblyâ€? effective:<br><br>For use as adjunctive therapy in the treatment of <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> (<span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable colon</span>, <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">spastic colon</span>, <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">mucous colitis</span>) and acute <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>.<br><br>May also be useful as adjunctive therapy in the treatment of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>.Â  IT HAS NOT BEEN SHOWN CONCLUSIVELY WHETHER ANTICHOLINERGIC/ANTISPASMODIC DRUGS AID IN THE HEALING OF A <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">DUODENAL ULCER</span>, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>, <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">obstructive uropathy</span> (for example, <span class="product-label-link" type="condition" conceptid="433813" conceptname="Bladder neck obstruction">bladder neck obstruction</span> due to <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>; severe <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> especially if complicated by toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>; <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>; <span class="product-label-link" type="condition" conceptid="4224004" conceptname="Hiatal hernia">hiatal hernia</span> associated with <span class="product-label-link" type="condition" conceptid="30437" conceptname="Gastro-esophageal reflux disease with esophagitis">reflux esophagitis</span>.<br><br>Donnatal ExtentabsÂ® is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the ingredients.Â  Phenobarbital is contraindicated in <span class="product-label-link" type="condition" conceptid="4120604" conceptname="Acute intermittent porphyria">acute intermittent porphyria</span> and in those patients in whom phenobarbital produces <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> and/or <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First">In the presence of a high environmental temperature, <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat prostration</span> can occur with belladonna alkaloids (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and heatstroke due to decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>).<br><br><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> may be an early symptom of incomplete <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, especially in patients with ileostomy or colostomy.Â  In this instance treatment with this drug would be inappropriate and possibly harmful.<br><br>Donnatal ExtentabsÂ® may produce <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. The patient should be warned, should these occur, not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery, and not to perform hazardous work.<br><br>Phenobarbital may decrease the effect of anticoagulants and necessitate larger doses of the anticoagulant for optimal effect. When phenobarbital is discontinued, the dose of the anticoagulant may have to be decreased.<br><br>Phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to those with a history of physical and/or psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> upon drugs.<br><br>Since barbiturates are metabolized in the liver, they should be used with caution and initial doses should be small in patients with hepatic dysfunction.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS:</h1>
<p class="First">Use with caution in patients with: <span class="product-label-link" type="condition" conceptid="4080146" conceptname="Autonomic neuropathy">autonomic neuropathy</span>, hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, coronary heart disease, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.<br><br>Belladonna alkaloids may produce a delay in gastric emptying (antral stasis) which would complicate the management of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>.<br><br>Theoretically, with overdosage, a curare-like action may occur.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8"></a><p></p>
<h1>Carcinogenesis, mutagenesis:</h1>
<p class="First">Long-term studies in animals have not been performed to evaluate carcinogenic potential.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-9"></a><p></p>
<h1>Pregnancy Category C:</h1>
<p class="First">Animal reproduction studies have not been conducted with Donnatal ExtentabsÂ®. It is not known whether Donnatal ExtentabsÂ® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Donnatal ExtentabsÂ® should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-10"></a><p></p>
<h1>Nursing mothers:</h1>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Donnatal ExtentabsÂ® is administered to a nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-11"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First">Adverse reactions may include <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">xerostomia</span>; <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitancy</span> and retention; <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>; <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>; <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>; <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span>; increased ocular <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>; <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">loss of taste</span> sense; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>; <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>; <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>: <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>; suppression of lactation; <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>; <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">bloated feeling</span>; <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>; severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> or drug idiosyncrasies, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and other dermal manifestations; and decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>. Acquired <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to barbituates consists chiefly in <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> that occur especially in persons who tend to have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and similar conditions. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> in this category include localized <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, particularly of the eyelids, cheeks, or lips, and erythematous <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>.Â  Rarely, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> (e.g. <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>) may be caused by phenobarbital and can prove fatal. The <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruption</span> may be associated with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and marked degenerative changes in the liver and other parenchymatous organs. In a few cases, <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> has been associated with the chronic use of phenobarbital. Elderly patients may react with symptoms of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, and other untoward manifestations to even small doses of the drug.<br><br>Phenobarbital may produce <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> in some patients, rather than a sedative effect.Â  In patients habituated to barbiturates, abrupt withdrawal may produce <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First">The dosage of Donnatal ExtentabsÂ® should be adjusted to the needs of the individual patient to assure symptomatic control with a minimum of adverse reactions. The usual dose is one tablet every twelve (12) hours.Â  If indicated, one tablet every eight (8) hours may be given.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-13"></a><p></p>
<h1>OVERDOSAGE:</h1>
<p class="First">The signs and symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>, hot and <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, dryness of the mouth, difficulty in swallowing, and CNS stimulation. Treatment should consist of gastric lavage, emetics, and activated charcoal.Â  If indicated, parenteral cholinergic agents such as physostigmine or bethanechol chloride should be added.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Donnatal ExtentabsÂ® Tablets are supplied as: film coated green, round, compressed tablets printed â€œP421â€? in black ink.<br><br>Bottles of 100 tablets<br>Bottles of 500 tablets<br><br>Store at 20-25Â°C (68-77Â°F) [See USP Controlled Room Temperature].Â  Protect from light and moisture.<br><br>Dispense in a well-closed, light-resistant container as defined in the USP using a child-resistant closure.<br><br>Also available: DonnatalÂ® Tablets in bottles of 100 and 1000 tablets and DonnatalÂ® Elixir in 4 fl oz bottles and 1 pint bottles.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<p class="First">Manufactured For:<br>PBM Pharmaceuticals, Inc.<br>Gordonsville, VA 22942<br><br>Manufactured By: <br>West-ward Pharmaceutical Corp.<br>Eatontown, NJ 07724 Revised June 2007</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<p class="First"><br><img alt="Label for 100 tab bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2064014b-6f8e-4232-88c2-d1870042abc7&amp;name=Donnatal%20Extentabs%20100s.jpg"><br><br>NDC 66213-421-10Â Â  Â 100 Tablets<br><br>Donnatal ExtentabsÂ®<br>Each Extentabs tablet contains:<br>Phenbarbital, USP . . . . 48.6 mg<br>Hyoscyamine Sulfate, USP . . . . . . .Â  0.3111 mg<br>Atropine Sulfate, USP . . . . . .Â Â  0.0582 mg<br>Scopolamine Hydrobromide, USP . . . . . . . . .Â  0.0195 mg<br>RX only<br><br>Usual Adult Usage:<br>See accompanying product literature for complete information.<br>Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â Â  Â U421-10-3<br>Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â Â Â  <br>PBM Pharmaceuticals, Inc.<br>Charlottesville, VA 22902<br>Exp. Date:<br>Control No:<br><br>Store at 20-25Â°C (68-77Â°F) [See USP Controlled Room Temperature].<br>Dispense in a well closed, light resistant container as defined in the USP using a child-resistant closure.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First"><img alt="Label for 500 tab bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2064014b-6f8e-4232-88c2-d1870042abc7&amp;name=Donnatal%20Extentabs%20500s.jpg"></p>
<p>NDC 66213-421-50Â Â  Â 500 Tablets<br>Donnatal ExtentabsÂ®<br>Each Extentabs tablet contains:<br>Phenbarbital, USP . . . . 48.6 mg<br>Hyoscyamine Sulfate, USP . . . . . . .Â  0.3111 mg<br>Atropine Sulfate, USP . . . . . .Â Â  0.0582 mg<br>Scopolamine Hydrobromide, USP . . . . . . . . .Â  0.0195 mg<br>RX only<br><br>Usual Adult Usage:<br>See accompanying product literature for complete information.<br>Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â Â Â  <br>Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â Â  Â U425-50-2<br>PBM Pharmaceuticals, Inc.<br>Charlottesville, VA 22902<br>Exp. Date:<br>Control No:<br><br>Store at 20-25Â°C (68-77Â°F) [See USP Controlled Room Temperature].<br>Dispense in a well closed, light resistant container as defined in the USP using a child-resistant closure.<br><br><br></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DONNATAL EXTENTABSÂ 		
					</strong><br><span class="contentTableReg">phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide tablet, film coated, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66213-421</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Phenobarbital</strong> (Phenobarbital) </td>
<td class="formItem">Phenobarbital</td>
<td class="formItem">48.6Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYOSCYAMINE SULFATE</strong> (HYOSCYAMINE) </td>
<td class="formItem">HYOSCYAMINE SULFATE</td>
<td class="formItem">0.3111Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ATROPINE SULFATE</strong> (ATROPINE) </td>
<td class="formItem">ATROPINE SULFATE</td>
<td class="formItem">0.0582Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>SCOPOLAMINE HYDROBROMIDE</strong> (SCOPOLAMINE) </td>
<td class="formItem">SCOPOLAMINE HYDROBROMIDE</td>
<td class="formItem">0.0195Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM SULFATE, UNSPECIFIED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2208 (4000 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYDEXTROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 2000</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">green (film coated) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">421</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66213-421-10</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:66213-421-50</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">05/07/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>PBM Pharmaceuticals, Inc
							(785470050)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">West-ward Pharmaceutical Corp.</td>
<td class="formItem"></td>
<td class="formItem">001230762</td>
<td class="formItem">manufacture, analysis, label, recovery, relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>03a3609f-520f-4e7b-8d7b-1652881723c0</div>
<div>Set id: 2064014b-6f8e-4232-88c2-d1870042abc7</div>
<div>Version: 1</div>
<div>Effective Time: 20111017</div>
</div>
</div>Â <div class="DistributorName">PBM Pharmaceuticals, Inc</div></p>
</body></html>
